Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Schizophrenia

  Free Subscription


Articles published in Psychol Med

Retrieve available abstracts of 144 articles:
HTML format



Single Articles


    November 2022
  1. SMUCNY J, Lesh TA, Niendam TA, Ragland JD, et al
    Evidence for functional improvement in reward anticipation in recent onset schizophrenia after one year of coordinated specialty care.
    Psychol Med. 2022 Nov 24:1-8. doi: 10.1017/S0033291722003592.
    PubMed     Abstract available


  2. KUO SS, Ventura J, Forsyth JK, Subotnik KL, et al
    Developmental trajectories of premorbid functioning predict cognitive remediation treatment response in first-episode schizophrenia.
    Psychol Med. 2022 Nov 9:1-10. doi: 10.1017/S0033291722003312.
    PubMed     Abstract available


  3. VALT C, Quarto T, Tavella A, Romanelli F, et al
    Reduced magnetic mismatch negativity: a shared deficit in psychosis and related risk.
    Psychol Med. 2022 Nov 2:1-9. doi: 10.1017/S003329172200321.
    PubMed     Abstract available


    October 2022
  4. D'ANDREA G, Lal J, Tosato S, Gayer-Anderson C, et al
    Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study.
    Psychol Med. 2022 Oct 28:1-11. doi: 10.1017/S003329172200335.
    PubMed     Abstract available


  5. GUPTA T, Osborne KJ, Nadig A, Haase CM, et al
    Alterations in facial expressions in individuals at risk for psychosis: a facial electromyography approach using emotionally evocative film clips.
    Psychol Med. 2022 Oct 26:1-10. doi: 10.1017/S0033291722003087.
    PubMed     Abstract available


  6. ANTONUCCI LA, Pergola G, Rampino A, Rocca P, et al
    Clinical and psychological factors associated with resilience in patients with schizophrenia: data from the Italian network for research on psychoses using machine learning.
    Psychol Med. 2022 Oct 11:1-12. doi: 10.1017/S003329172200294.
    PubMed     Abstract available


    September 2022
  7. VOUGA RIBEIRO N, Tavares V, Bramon E, Toulopoulou T, et al
    Effects of psychosis-associated genetic markers on brain volumetry: a systematic review of replicated findings and an independent validation.
    Psychol Med. 2022 Sep 28:1-16. doi: 10.1017/S0033291722002896.
    PubMed     Abstract available


  8. WANG YZ, Weng X, Zhang TM, Li M, et al
    Effectiveness of enhancing contact model on reducing family caregiving burden and improving psychological wellbeing among caregivers of persons with schizophrenia in rural China.
    Psychol Med. 2022 Sep 26:1-11. doi: 10.1017/S0033291722002987.
    PubMed     Abstract available


  9. FAN F, Tan S, Liu S, Chen S, et al
    Subcortical structures associated with childhood trauma and perceived stress in schizophrenia.
    Psychol Med. 2022 Sep 26:1-9. doi: 10.1017/S0033291722002860.
    PubMed     Abstract available


  10. LIN JY, Yeh LL, Pan YJ
    Exposure to psychotropic medications and mortality in schizophrenia: a 5-year national cohort study.
    Psychol Med. 2022 Sep 22:1-10. doi: 10.1017/S0033291722002732.
    PubMed     Abstract available


  11. RADHAKRISHNAN R, Pries LK, Erzin G, Ten Have M, et al
    Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis.
    Psychol Med. 2022 Sep 12:1-7. doi: 10.1017/S0033291722002756.
    PubMed     Abstract available


  12. MALLET J, Godin O, Dansou Y, Mazer N, et al
    Current (but not ex) cigarette smoking is associated with worse cognitive performances in schizophrenia: results from the FACE-SZ cohort.
    Psychol Med. 2022 Sep 8:1-12. doi: 10.1017/S0033291722002574.
    PubMed     Abstract available


  13. RAMSAY IS, Mueller B, Ma Y, Shen C, et al
    Thalamocortical connectivity and its relationship with symptoms and cognition across the psychosis continuum.
    Psychol Med. 2022 Sep 1:1-10. doi: 10.1017/S0033291722002793.
    PubMed     Abstract available


  14. SARPAL DK, Tarcijonas G, Calabro FJ, Foran W, et al
    Context-specific abnormalities of the central executive network in first-episode psychosis: relationship with cognition.
    Psychol Med. 2022;52:2299-2308.
    PubMed     Abstract available


  15. FAN F, Tan S, Huang J, Chen S, et al
    Functional disconnection between subsystems of the default mode network in schizophrenia.
    Psychol Med. 2022;52:2270-2280.
    PubMed     Abstract available


  16. GUIMOND S, Ling G, Drodge J, Matheson H, et al
    Functional connectivity associated with improvement in emotion management after cognitive enhancement therapy in early-course schizophrenia.
    Psychol Med. 2022;52:2245-2254.
    PubMed     Abstract available


    August 2022
  17. SELVAGGI P, Jauhar S, Kotoula V, Pepper F, et al
    Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response.
    Psychol Med. 2022 Aug 25:1-11. doi: 10.1017/S0033291722002288.
    PubMed     Abstract available


  18. ROGNLI EB, Taipale H, Hjorthoj C, Mittendorfer-Rutz E, et al
    Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016.
    Psychol Med. 2022 Aug 19:1-10. doi: 10.1017/S003329172200229.
    PubMed     Abstract available


  19. AMORETTI S, Rabelo-da-Ponte FD, Garriga M, Forte MF, et al
    Obstetric complications and cognition in schizophrenia: a systematic review and meta-analysis.
    Psychol Med. 2022 Aug 18:1-11. doi: 10.1017/S0033291722002409.
    PubMed     Abstract available


  20. PRASANNAKUMAR A, Kumar V, Rao NP
    Trust and psychosis: a systematic review and meta-analysis.
    Psychol Med. 2022 Aug 17:1-9. doi: 10.1017/S0033291722002562.
    PubMed     Abstract available


  21. OHI K, Nishizawa D, Sugiyama S, Takai K, et al
    Cognitive performances across individuals at high genetic risk for schizophrenia, high genetic risk for bipolar disorder, and low genetic risks: a combined polygenic risk score approach.
    Psychol Med. 2022 Aug 16:1-10. doi: 10.1017/S0033291722001271.
    PubMed     Abstract available


  22. NUECHTERLEIN KH, McEwen SC, Ventura J, Subotnik KL, et al
    Aerobic exercise enhances cognitive training effects in first-episode schizophrenia: randomized clinical trial demonstrates cognitive and functional gains.
    Psychol Med. 2022 Aug 8:1-11. doi: 10.1017/S0033291722001696.
    PubMed     Abstract available


  23. GURVICH C, Thomas N, Hudaib AR, Van Rheenen TE, et al
    The relationship between cognitive clusters and telomere length in bipolar-schizophrenia spectrum disorders.
    Psychol Med. 2022 Aug 3:1-8. doi: 10.1017/S0033291722002148.
    PubMed     Abstract available


    July 2022
  24. HEDGES EP, See C, Si S, McGuire P, et al
    Meta-analysis of longitudinal neurocognitive performance in people at clinical high-risk for psychosis.
    Psychol Med. 2022 Jul 13:1-8. doi: 10.1017/S0033291722001830.
    PubMed     Abstract available


  25. STURUP AE, Nordentoft M, Jimenez-Solem E, Osler M, et al
    Discontinuation of antipsychotics in individuals with first-episode schizophrenia and its association to functional outcomes, hospitalization and death: a register-based nationwide follow-up study.
    Psychol Med. 2022 Jul 12:1-9. doi: 10.1017/S0033291722002021.
    PubMed     Abstract available


  26. DI PRINZIO P, Bjork J, Valuri G, Ambrosi T, et al
    Development and initial validation of a multivariable predictive Early Adversity Scale for Schizophrenia (EAS-Sz) using register data to quantify environmental risk for adult schizophrenia diagnosis after childhood exposure to adversity.
    Psychol Med. 2022 Jul 12:1-11. doi: 10.1017/S0033291722001945.
    PubMed     Abstract available


  27. SEITZ-HOLLAND J, Nagele FL, Kubicki M, Pasternak O, et al
    Shared and distinct white matter abnormalities in adolescent-onset schizophrenia and adolescent-onset psychotic bipolar disorder.
    Psychol Med. 2022 Jul 7:1-13. doi: 10.1017/S003329172200160.
    PubMed     Abstract available


  28. CAI XL, Pu CC, Zhou SZ, Wang Y, et al
    Anterior cingulate glutamate levels associate with functional activation and connectivity during sensory integration in schizophrenia: a multimodal (1)H-MRS and fMRI study.
    Psychol Med. 2022 Jul 6:1-11. doi: 10.1017/S0033291722001817.
    PubMed     Abstract available


  29. VENTURA AMB, Hayes RD, Fonseca de Freitas D
    Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review.
    Psychol Med. 2022 Jul 5:1-12. doi: 10.1017/S0033291722001878.
    PubMed     Abstract available


  30. GUNASEKERA B, Wilson R, O'Neill A, Blest-Hopley G, et al
    Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
    Psychol Med. 2022 Jul 1:1-10. doi: 10.1017/S0033291722001672.
    PubMed     Abstract available


  31. LATRECHE C, Maeder J, Mancini V, Bortolin K, et al
    Altered developmental trajectories of verbal learning skills in 22q11.2DS: associations with hippocampal development and psychosis.
    Psychol Med. 2022 Jul 1:1-10. doi: 10.1017/S0033291722001842.
    PubMed     Abstract available


  32. VAN OS J, Pries LK, Ten Have M, de Graaf R, et al
    Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway.
    Psychol Med. 2022;52:1910-1922.
    PubMed     Abstract available


    June 2022
  33. TOWNSEND L, Pillinger T, Selvaggi P, Veronese M, et al
    Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of (18)FDG-PET studies in schizophrenia.
    Psychol Med. 2022 Jun 22:1-18. doi: 10.1017/S003329172200174.
    PubMed     Abstract available


  34. FUENTES-CLARAMONTE P, Salgado-Pineda P, Argila-Plaza I, Garcia-Leon MA, et al
    Neural correlates of referential/persecutory delusions in schizophrenia: examination using fMRI and a virtual reality underground travel paradigm.
    Psychol Med. 2022 Jun 22:1-8. doi: 10.1017/S0033291722001751.
    PubMed     Abstract available


  35. DE HAAN L, Linszen D, Wouters L, Zwinderman K, et al
    Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial.
    Psychol Med. 2022 Jun 8:1-8. doi: 10.1017/S003329172200099.
    PubMed     Abstract available


  36. RABALLO A, Poletti M, Preti A
    Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis.
    Psychol Med. 2022 Jun 3:1-11. doi: 10.1017/S0033291722001428.
    PubMed     Abstract available


  37. WANG HE, Cheng CM, Bai YM, Hsu JW, et al
    Familial coaggregation of major psychiatric disorders in first-degree relatives of individuals with autism spectrum disorder: a nationwide population-based study.
    Psychol Med. 2022;52:1437-1447.
    PubMed     Abstract available


    May 2022
  38. HOMAN P, Schooler NR, Brunette MF, Rotondi A, et al
    Relapse prevention through health technology program reduces hospitalization in schizophrenia.
    Psychol Med. 2022 May 30:1-7. doi: 10.1017/S0033291722000794.
    PubMed     Abstract available


  39. DESOUZA DD, Tang SX, Danilewitz M
    The burgeoning role of speech and language assessment in schizophrenia spectrum disorders.
    Psychol Med. 2022 May 18:1-2. doi: 10.1017/S0033291722001325.
    PubMed    


  40. CULBERT KM, Thakkar KN, Klump KL
    Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk.
    Psychol Med. 2022 May 18:1-9. doi: 10.1017/S0033291722001143.
    PubMed     Abstract available


  41. CZEPIELEWSKI LS, Alliende LM, Castaneda CP, Castro M, et al
    Effects of Socioeconomic Status in Cognition of People with Schizophrenia: Results From a Latin American Collaboration Network with 1175 Subjects - Corrigendum.
    Psychol Med. 2022 May 9:1. doi: 10.1017/S0033291721003949.
    PubMed    


  42. TERMORSHUIZEN F, Selten JP
    Risk of psychosis among migrants to the Netherlands by time since arrival.
    Psychol Med. 2022 May 5:1-10. doi: 10.1017/S0033291722001192.
    PubMed     Abstract available


    April 2022
  43. BADAL VD, Depp CA, Harvey PD, Ackerman RA, et al
    Confidence, accuracy judgments and feedback in schizophrenia and bipolar disorder: a time series network analysis.
    Psychol Med. 2022 Apr 28:1-10. doi: 10.1017/S0033291722000939.
    PubMed     Abstract available


  44. FREEMAN D, Rosebrock L, Waite F, Loe BS, et al
    Virtual reality (VR) therapy for patients with psychosis: satisfaction and side effects.
    Psychol Med. 2022 Apr 28:1-12. doi: 10.1017/S0033291722001167.
    PubMed     Abstract available


  45. CATALAN A, Aymerich C, Bilbao A, Pedruzo B, et al
    Psychosis and Substance Abuse increase the COVID-19 mortality risk.
    Psychol Med. 2022 Apr 12:1-23. doi: 10.1017/S0033291722000976.
    PubMed    


  46. JANG SK, Saunders G, Liu M, Jiang Y, et al
    Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder.
    Psychol Med. 2022;52:968-978.
    PubMed     Abstract available


    March 2022
  47. ROBINSON T, Ali MU, Easterbrook B, Hall W, et al
    Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis.
    Psychol Med. 2022 Mar 24:1-11. doi: 10.1017/S0033291722000502.
    PubMed     Abstract available


  48. VITA A, Barlati S, Ceraso A, Deste G, et al
    Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Psychol Med. 2022 Mar 8:1-11. doi: 10.1017/S0033291722000319.
    PubMed     Abstract available


  49. FLAATEN CB, Melle I, Gardsjord E, Bjella T, et al
    Course of intellectual functioning in schizophrenia and bipolar disorder: a 10-year follow-up study.
    Psychol Med. 2022 Mar 8:1-9. doi: 10.1017/S0033291721004645.
    PubMed     Abstract available


    February 2022
  50. DEMJAHA A, Galderisi S, Glenthoj B, Arango C, et al
    Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study.
    Psychol Med. 2022 Feb 24:1-9. doi: 10.1017/S0033291722000010.
    PubMed     Abstract available


  51. HUANG LC, Lin SH, Tseng HH, Chen KC, et al
    Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study.
    Psychol Med. 2022 Feb 24:1-8. doi: 10.1017/S003329172100533.
    PubMed     Abstract available


  52. WATSON AJ, Giordano A, Suckling J, Barnes TRE, et al
    Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers.
    Psychol Med. 2022 Feb 18:1-10. doi: 10.1017/S0033291721004815.
    PubMed     Abstract available


  53. LI M, Deng W, Li Y, Zhao L, et al
    Ameliorative patterns of grey matter in patients with first-episode and treatment-naive schizophrenia.
    Psychol Med. 2022 Feb 15:1-11. doi: 10.1017/S0033291722000058.
    PubMed     Abstract available


  54. DENG W, Addington J, Bearden CE, Cadenhead KS, et al
    Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes.
    Psychol Med. 2022 Feb 11:1-8. doi: 10.1017/S0033291722000277.
    PubMed     Abstract available


  55. HUI CLM, Wong AKH, Ho ECN, Lam BST, et al
    Effectiveness and optimal duration of early intervention treatment in adult-onset psychosis: a randomized clinical trial.
    Psychol Med. 2022 Feb 11:1-13. doi: 10.1017/S0033291721004189.
    PubMed     Abstract available


  56. DAN-GLAUSER E, Framorando D, Solida-Tozzi A, Golay P, et al
    Evolution of impulsivity levels in relation to early cannabis use in violent patients in the early phase of psychosis.
    Psychol Med. 2022 Feb 10:1-10. doi: 10.1017/S0033291721005316.
    PubMed     Abstract available


  57. PICO-PEREZ M, Vieira R, Fernandez-Rodriguez M, De Barros MAP, et al
    Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients.
    Psychol Med. 2022 Feb 7:1-11. doi: 10.1017/S0033291721005523.
    PubMed     Abstract available


  58. WILKINSON ID, Mahmood T, Yasmin SF, Tomlinson A, et al
    In memory of Professor Iain Wilkinson: cognitive and neuroimaging endophenotypes in a consanguineous schizophrenia multiplex family.
    Psychol Med. 2022 Feb 7:1-9. doi: 10.1017/S0033291721005250.
    PubMed     Abstract available


    January 2022
  59. RODRIGUEZ V, Alameda L, Quattrone D, Tripoli G, et al
    Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.
    Psychol Med. 2022 Jan 25:1-10. doi: 10.1017/S0033291721005456.
    PubMed     Abstract available


  60. LEPAGE M, Bowie CR, Montreuil T, Baer L, et al
    Manualized group cognitive behavioral therapy for social anxiety in first-episode psychosis: a randomized controlled trial.
    Psychol Med. 2022 Jan 11:1-10. doi: 10.1017/S0033291721005328.
    PubMed     Abstract available


  61. SU W, Yuan A, Tang Y, Xu L, et al
    Effects of polygenic risk of schizophrenia on interhemispheric callosal white matter integrity and frontotemporal functional connectivity in first-episode schizophrenia.
    Psychol Med. 2022 Jan 7:1-10. doi: 10.1017/S0033291721004840.
    PubMed     Abstract available


  62. SCHICK A, van Winkel R, Lin BD, Luykx JJ, et al
    Polygenic risk, familial liability and stress reactivity in psychosis: an experience sampling study.
    Psychol Med. 2022 Jan 7:1-10. doi: 10.1017/S0033291721004761.
    PubMed     Abstract available


  63. MILLGATE E, Hide O, Lawrie SM, Murray RM, et al
    Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis.
    Psychol Med. 2022;52:1-13.
    PubMed     Abstract available


  64. JONES HJ, Hammerton G, McCloud T, Hines LA, et al
    Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence.
    Psychol Med. 2022;52:132-139.
    PubMed     Abstract available


  65. RABALLO A, Poletti M
    Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
    Psychol Med. 2022;52:184-187.
    PubMed     Abstract available


    December 2021
  66. PATEL GH, Arkin SC, Ruiz-Betancourt DR, DeBaun HM, et al
    What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia.
    Psychol Med. 2021;51:2923-2932.
    PubMed     Abstract available


  67. LAVALLE L, Donde C, Gaweda L, Brunelin J, et al
    Impaired self-recognition in individuals with no full-blown psychotic symptoms represented across the continuum of psychosis: a meta-analysis.
    Psychol Med. 2021;51:2864-2874.
    PubMed     Abstract available


  68. VERDOUX H, Quiles C, Bon L, Chereau-Boudet I, et al
    Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers.
    Psychol Med. 2021;51:2789-2797.
    PubMed     Abstract available


    November 2021
  69. ROTENBERG M, Tuck A, Anderson KK, McKenzie K, et al
    Neighbourhood-level social capital, marginalisation, and the incidence of schizophrenia and schizoaffective disorder in Toronto, Canada: a retrospective population-based cohort study.
    Psychol Med. 2021 Nov 23:1-9. doi: 10.1017/S003329172100458.
    PubMed     Abstract available


  70. ERZIN G, Pries LK, Dimitrakopoulos S, Ralli I, et al
    Association between exposome score for schizophrenia and functioning in first-episode psychosis: results from the Athens first-episode psychosis research study.
    Psychol Med. 2021 Nov 18:1-10. doi: 10.1017/S0033291721004542.
    PubMed     Abstract available


  71. BRAND BA, Haveman YRA, de Beer F, de Boer JN, et al
    Antipsychotic medication for women with schizophrenia spectrum disorders.
    Psychol Med. 2021 Nov 12:1-15. doi: 10.1017/S0033291721004591.
    PubMed     Abstract available


  72. MERCHANT JT, Moran EK, Strube MJ, Barch DM, et al
    Correlates of real-world goal-directed behavior in schizophrenia.
    Psychol Med. 2021 Nov 12:1-9. doi: 10.1017/S0033291721004281.
    PubMed     Abstract available


  73. HODGINS S, Eronen M, Freese R, Hart S, et al
    Correspondence regarding De Girolamo et al., 2021 'A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project'.
    Psychol Med. 2021 Nov 2:1-2. doi: 10.1017/S0033291721004347.
    PubMed    


  74. BARRON DS
    Commentary: the ethical challenges of machine learning in psychiatry: a focus on data, diagnosis, and treatment.
    Psychol Med. 2021;51:2522-2524.
    PubMed     Abstract available


    October 2021
  75. OOMEN PP, Begemann MJH, Brand BA, de Haan L, et al
    Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis.
    Psychol Med. 2021 Oct 19:1-11. doi: 10.1017/S0033291721004153.
    PubMed     Abstract available


  76. LO LLH, Lee EHM, Hui CLM, Chong CSY, et al
    Effect of high-endurance exercise intervention on sleep-dependent procedural memory consolidation in individuals with schizophrenia: a randomized controlled trial.
    Psychol Med. 2021 Oct 7:1-13. doi: 10.1017/S0033291721003196.
    PubMed     Abstract available


    September 2021
  77. SHENG D, Pu W, Linli Z, Tian GL, et al
    Aberrant global and local dynamic properties in schizophrenia with instantaneous phase method based on Hilbert transform.
    Psychol Med. 2021 Sep 30:1-11. doi: 10.1017/S0033291721003895.
    PubMed     Abstract available


  78. EMSLEY R, du Plessis S, Phahladira L, Luckhoff HK, et al
    Antipsychotic treatment effects and structural MRI brain changes in schizophrenia.
    Psychol Med. 2021 Sep 23:1-10. doi: 10.1017/S0033291721003809.
    PubMed     Abstract available


  79. PAQUIN V, Cupo L, Malla AK, Iyer SN, et al
    Dynamic association of the first identifiable symptom with rapidity of progression to first-episode psychosis.
    Psychol Med. 2021 Sep 20:1-9. doi: 10.1017/S0033291721003755.
    PubMed     Abstract available


  80. DE GIROLAMO G, Iozzino L, Ferrari C, Gosek P, et al
    A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project.
    Psychol Med. 2021 Sep 13:1-11. doi: 10.1017/S0033291721003433.
    PubMed     Abstract available


  81. GARRIDO-TORRES N, Rocha-Gonzalez I, Alameda L, Rodriguez-Gangoso A, et al
    Metabolic syndrome in antipsychotic-naive patients with first-episode psychosis: a systematic review and meta-analysis.
    Psychol Med. 2021 Sep 8:1-14. doi: 10.1017/S0033291721002853.
    PubMed     Abstract available


  82. LI X, Deng W, Xue R, Wang Q, et al
    Auditory event-related potentials, neurocognition, and global functioning in drug naive first-episode schizophrenia and bipolar disorder.
    Psychol Med. 2021 Sep 3:1-10. doi: 10.1017/S0033291721002130.
    PubMed     Abstract available


  83. FRAWLEY E, Cowman M, Lepage M, Donohoe G, et al
    Social and occupational recovery in early psychosis: a systematic review and meta-analysis of psychosocial interventions.
    Psychol Med. 2021 Sep 3:1-12. doi: 10.1017/S003329172100341.
    PubMed     Abstract available


  84. HJERN A, Palacios J, Vinnerljung B
    Early childhood adversity and non-affective psychosis: a study of refugees and international adoptees in Sweden.
    Psychol Med. 2021 Sep 2:1-10. doi: 10.1017/S003329172100355.
    PubMed     Abstract available


  85. KIM M, Kim T, Hwang WJ, Lho SK, et al
    Forecasting prognostic trajectories with mismatch negativity in early psychosis.
    Psychol Med. 2021 Sep 2:1-11. doi: 10.1017/S0033291721003068.
    PubMed     Abstract available


  86. SAMI M, Quattrone D, Ferraro L, Tripoli G, et al
    Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls.
    Psychol Med. 2021;51:2074-2082.
    PubMed     Abstract available


  87. CSUKLY G, Szabo A, Polgar P, Farkas K, et al
    Fronto-thalamic structural and effective connectivity and delusions in schizophrenia: a combined DTI/DCM study.
    Psychol Med. 2021;51:2083-2093.
    PubMed     Abstract available


  88. BALLESTEROS A, Sanchez Torres AM, Lopez-Ilundain J, Mezquida G, et al
    The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Psychol Med. 2021;51:2044-2053.
    PubMed     Abstract available


  89. ZHANG T, Xu L, Chen Y, Wei Y, et al
    Conversion to psychosis in adolescents and adults: similar proportions, different predictors.
    Psychol Med. 2021;51:2003-2011.
    PubMed     Abstract available


    August 2021
  90. MARTLAND R, Teasdale S, Murray RM, Gardner-Sood P, et al
    Dietary intake, physical activity and sedentary behaviour patterns in a sample with established psychosis and associations with mental health symptomatology.
    Psychol Med. 2021 Aug 23:1-11. doi: 10.1017/S0033291721003147.
    PubMed     Abstract available


  91. ALLARDYCE J, Hollander AC, Rahman S, Dalman C, et al
    Association of trauma, post-traumatic stress disorder and non-affective psychosis across the life course: a nationwide prospective cohort study.
    Psychol Med. 2021 Aug 20:1-9. doi: 10.1017/S0033291721003287.
    PubMed     Abstract available


  92. COORS A, Imtiaz MA, Boenniger MM, Aziz NA, et al
    Polygenic risk scores for schizophrenia are associated with oculomotor endophenotypes.
    Psychol Med. 2021 Aug 20:1-9. doi: 10.1017/S0033291721003251.
    PubMed     Abstract available


  93. MOFFA G, Kuipers J, Carra G, Crocamo C, et al
    Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs.
    Psychol Med. 2021 Aug 5:1-8. doi: 10.1017/S0033291721002920.
    PubMed     Abstract available


  94. LEMVIGH C, Brouwer R, Hilker R, Anhoj S, et al
    The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study.
    Psychol Med. 2021 Aug 5:1-11. doi: 10.1017/S0033291721002749.
    PubMed     Abstract available


  95. DE BOER JN, Voppel AE, Brederoo SG, Schnack HG, et al
    Acoustic speech markers for schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool.
    Psychol Med. 2021 Aug 4:1-11. doi: 10.1017/S0033291721002804.
    PubMed     Abstract available


  96. ZHAO W, Zhang Q, Chen X, Li Y, et al
    The VNTR of the AS3MT gene is associated with brain activations during a memory span task and their training-induced plasticity.
    Psychol Med. 2021;51:1927-1932.
    PubMed     Abstract available


    July 2021
  97. WIESSNER I, Falchi M, Palhano-Fontes F, Feilding A, et al
    LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Psychol Med. 2021 Jul 13:1-15. doi: 10.1017/S0033291721002531.
    PubMed     Abstract available


  98. JOHNSON EC, Kapoor M, Hatoum AS, Zhou H, et al
    Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder.
    Psychol Med. 2021 Jul 7:1-9. doi: 10.1017/S003329172100266.
    PubMed     Abstract available


  99. FAGERLUND B, Pantelis C, Jepsen JRM, Raghava JM, et al
    Differential effects of age at illness onset on verbal memory functions in antipsychotic-naive schizophrenia patients aged 12-43 years.
    Psychol Med. 2021;51:1570-1580.
    PubMed     Abstract available


  100. NEUMANN SR, Glue P, Linscott RJ
    Aberrant salience and reward processing: a comparison of measures in schizophrenia and anxiety.
    Psychol Med. 2021;51:1507-1515.
    PubMed     Abstract available


  101. JONGSMA HE, Gayer-Anderson C, Tarricone I, Velthorst E, et al
    Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.
    Psychol Med. 2021;51:1536-1548.
    PubMed     Abstract available


  102. LIEBERS DT, Pirooznia M, Ganna A, Goes FS, et al
    Discriminating bipolar depression from major depressive disorder with polygenic risk scores.
    Psychol Med. 2021;51:1451-1458.
    PubMed     Abstract available


  103. CHRETIEN B, Lelong-Boulouard V, Chantepie S, Sassier M, et al
    Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase((R)).
    Psychol Med. 2021;51:1459-1466.
    PubMed     Abstract available


  104. RAUSCHENBERG C, Reininghaus U, Ten Have M, de Graaf R, et al
    The jumping to conclusions reasoning bias as a cognitive factor contributing to psychosis progression and persistence: findings from NEMESIS-2.
    Psychol Med. 2021;51:1696-1703.
    PubMed     Abstract available


  105. KOWALCZYK OS, Pauls AM, Fuste M, Williams SCR, et al
    Neurocognitive correlates of working memory and emotional processing in postpartum psychosis: an fMRI study.
    Psychol Med. 2021;51:1724-1732.
    PubMed     Abstract available


  106. CUESTA MJ, Lecumberri P, Moreno-Izco L, Lopez-Ilundain JM, et al
    Motor abnormalities and basal ganglia in first-episode psychosis (FEP).
    Psychol Med. 2021;51:1625-1636.
    PubMed     Abstract available


    June 2021
  107. CZEPIELEWSKI LS, Alliende LM, Castaneda CP, Castro M, et al
    Effects of socioeconomic status in cognition of people with schizophrenia: results from a Latin American collaboration network with 1175 subjects.
    Psychol Med. 2021 Jun 23:1-12. doi: 10.1017/S0033291721002403.
    PubMed     Abstract available


  108. SCHOFIELD P, Das-Munshi J, Webb RT, Horsdal HT, et al
    Lack of fit with the neighbourhood social environment as a risk factor for psychosis - a national cohort study.
    Psychol Med. 2021 Jun 18:1-9. doi: 10.1017/S0033291721002233.
    PubMed     Abstract available


  109. STRAUSS GP, Bartolomeo LA, Luther L
    Reduced willingness to expend effort for rewards is associated with risk for conversion and negative symptom severity in youth at clinical high-risk for psychosis.
    Psychol Med. 2021 Jun 14:1-8. doi: 10.1017/S003329172100204.
    PubMed     Abstract available


  110. DONG D, Yao D, Wang Y, Hong SJ, et al
    Compressed sensorimotor-to-transmodal hierarchical organization in schizophrenia.
    Psychol Med. 2021 Jun 8:1-14. doi: 10.1017/S0033291721002129.
    PubMed     Abstract available


  111. QUATTRONE D, Ferraro L, Tripoli G, La Cascia C, et al
    Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
    Psychol Med. 2021;51:1329-1337.
    PubMed     Abstract available


  112. KING M, Jones R, Petersen I, Hamilton F, et al
    Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses.
    Psychol Med. 2021;51:1373-1381.
    PubMed     Abstract available


  113. OSBORNE KJ, Damme KSF, Gupta T, Dean DJ, et al
    Timing dysfunction and cerebellar resting state functional connectivity abnormalities in youth at clinical high-risk for psychosis.
    Psychol Med. 2021;51:1289-1298.
    PubMed     Abstract available


    May 2021
  114. STAFFORD J, Dykxhoorn J, Sommerlad A, Dalman C, et al
    Association between risk of dementia and very late-onset schizophrenia-like psychosis: a Swedish population-based cohort study.
    Psychol Med. 2021 May 25:1-9. doi: 10.1017/S0033291721002099.
    PubMed     Abstract available


  115. O'DONOGHUE B, Lyne J, Roche E, Mifsud N, et al
    Risk of first-episode psychosis in migrants to the Republic of Ireland.
    Psychol Med. 2021 May 25:1-8. doi: 10.1017/S003329172100177.
    PubMed     Abstract available


  116. LINDGREN M, Kuvaja H, Jokela M, Therman S, et al
    Predictive validity of psychosis risk models when applied to adolescent psychiatric patients.
    Psychol Med. 2021 May 24:1-12. doi: 10.1017/S0033291721001938.
    PubMed     Abstract available


  117. AYESA-ARRIOLA R, Miguel-Corredera M, de la Foz VO, Neergaard KD, et al
    Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort.
    Psychol Med. 2021 May 6:1-12. doi: 10.1017/S0033291721001112.
    PubMed     Abstract available


  118. WEARNE TA, McDonald S
    Social cognition v. emotional intelligence in first-episode psychosis: are they the same?
    Psychol Med. 2021;51:1229-1230.
    PubMed    


    April 2021
  119. ZHANG R, Kuja-Halkola R, Birgegard A, Larsson H, et al
    Association of family history of schizophrenia and clinical outcomes in individuals with eating disorders.
    Psychol Med. 2021 Apr 30:1-8. doi: 10.1017/S0033291721001574.
    PubMed     Abstract available


  120. MCHUGO M, Avery S, Armstrong K, Rogers BP, et al
    Anterior hippocampal dysfunction in early psychosis: a 2-year follow-up study.
    Psychol Med. 2021 Apr 20:1-10. doi: 10.1017/S0033291721001318.
    PubMed     Abstract available


  121. SEDGWICK O, Hardy A, Newbery K, Cella M, et al
    A systematic review of adherence to group interventions in psychosis: do people attend?
    Psychol Med. 2021 Apr 16:1-9. doi: 10.1017/S0033291721000404.
    PubMed     Abstract available


  122. JOO SW, Kim H, Jo YT, Choi YJ, et al
    Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
    Psychol Med. 2021 Apr 15:1-8. doi: 10.1017/S0033291721001379.
    PubMed     Abstract available


  123. SWERDLOW NR, Bhakta SG, Talledo J, Benster L, et al
    Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course.
    Psychol Med. 2021 Apr 14:1-9. doi: 10.1017/S0033291721001239.
    PubMed     Abstract available


  124. VAN LEEUWEN JMC, Vinkers CH, Vink M, Kahn RS, et al
    Disrupted upregulation of salience network connectivity during acute stress in siblings of schizophrenia patients.
    Psychol Med. 2021;51:1038-1048.
    PubMed     Abstract available


  125. GUO JY, Lesh TA, Niendam TA, Ragland JD, et al
    Brain free water alterations in first-episode psychosis: a longitudinal analysis of diagnosis, course of illness, and medication effects.
    Psychol Med. 2021;51:1001-1010.
    PubMed     Abstract available


  126. POKORNY VJ, Lano TJ, Schallmo MP, Olman CA, et al
    Reduced influence of perceptual context in schizophrenia: behavioral and neurophysiological evidence.
    Psychol Med. 2021;51:786-794.
    PubMed     Abstract available


  127. PEREZ J, Jones PB
    Breaking the web: life beyond the at-risk mental state for psychosis.
    Psychol Med. 2021;51:934-939.
    PubMed     Abstract available


    March 2021
  128. O'NEILL A, Wilson R, Blest-Hopley G, Annibale L, et al
    Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    Psychol Med. 2021;51:596-606.
    PubMed     Abstract available


  129. HUANG MH, Cheng CM, Tsai SJ, Bai YM, et al
    Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: a nationwide study.
    Psychol Med. 2021;51:680-687.
    PubMed     Abstract available


  130. NKIRE N, Scully PJ, Browne DJ, Baldwin PA, et al
    Systematic epidemiological and clinical comparisons across all 12 DSM-IV psychotic diagnoses in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).
    Psychol Med. 2021;51:607-616.
    PubMed     Abstract available


  131. ZHANG T, Xu L, Li H, Woodberry KA, et al
    Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program.
    Psychol Med. 2021;51:653-660.
    PubMed     Abstract available


  132. HJORTHOJ C, Larsen MO, Starzer MSK, Nordentoft M, et al
    Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016.
    Psychol Med. 2021;51:617-622.
    PubMed     Abstract available


    February 2021
  133. SIAFIS S, Davis JM, Leucht S
    Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature.
    Psychol Med. 2021;51:522-524.
    PubMed    


  134. MONCRIEFF J, Cohen D
    Antipsychotics as particular types of sedatives.
    Psychol Med. 2021;51:521.
    PubMed    


  135. HERBENER ES, Harrow M
    Course and symptom and functional correlates of passivity symptoms in schizophrenia: an 18-year multi-follow-up longitudinal study.
    Psychol Med. 2021;51:503-510.
    PubMed     Abstract available


  136. LIU Y, Mendonca M, Johnson S, O'Reilly H, et al
    Testing the neurodevelopmental, trauma and developmental risk factor models of psychosis using a naturalistic experiment.
    Psychol Med. 2021;51:460-469.
    PubMed     Abstract available


  137. HJORTHOJ C, Uddin MJ, Wimberley T, Dalsgaard S, et al
    No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder.
    Psychol Med. 2021;51:479-484.
    PubMed     Abstract available


    January 2021
  138. VIEIRA S, Gong Q, Scarpazza C, Lui S, et al
    Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis.
    Psychol Med. 2021;51:340-350.
    PubMed     Abstract available


  139. DAVIES SJC, Iwajomo T, de Oliveira C, Versloot J, et al
    The impact of psychiatric and medical comorbidity on the risk of mortality: a population-based analysis.
    Psychol Med. 2021;51:320-328.
    PubMed     Abstract available


  140. ODUOLA S, Das-Munshi J, Bourque F, Gayer-Anderson C, et al
    Change in incidence rates for psychosis in different ethnic groups in south London: findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study.
    Psychol Med. 2021;51:300-309.
    PubMed     Abstract available


  141. AYESA-ARRIOLA R, Ortiz-Garcia de la Foz V, Martinez-Garcia O, Setien-Suero E, et al
    Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort.
    Psychol Med. 2021;51:264-277.
    PubMed     Abstract available


  142. MARTIN-SUBERO M, Fuentes-Claramonte P, Salgado-Pineda P, Salavert J, et al
    Autobiographical memory and default mode network function in schizophrenia: an fMRI study.
    Psychol Med. 2021;51:121-128.
    PubMed     Abstract available


  143. BRUCATO G, First MB, Dishy GA, Samuel SS, et al
    Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients.
    Psychol Med. 2021;51:112-120.
    PubMed     Abstract available


  144. SMART SE, Kepinska AP, Murray RM, MacCabe JH, et al
    Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies.
    Psychol Med. 2021;51:44-53.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: